Page last updated: 2024-08-18

cyclohexene and Diabetes Mellitus, Type 2

cyclohexene has been researched along with Diabetes Mellitus, Type 2 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Backes, BJ; Ballaron, SJ; Beno, DW; Fryer, RM; Judd, AS; Kempf-Grote, AJ; Li, X; Longenecker, K; Lubben, TH; Madar, DJ; Mika, AK; Mulhern, M; Pei, Z; Preusser, LC; Reinhart, GA; Sham, HL; Stashko, MA; Stewart, KD; Trevillyan, JM; von Geldern, TW; Yong, H; Zinker, BA	1
Backes, BJ; Ballaron, SJ; Beno, DW; Black-Schaefer, C; Hamilton, GL; Kempf-Grote, AJ; Kopecka, H; Lai, C; Longenecker, K; Lubben, TH; Madar, DJ; Mika, AK; Pei, Z; Sham, HL; Stashko, MA; Stewart, K; Tian, Z; Trevillyan, JM; von Geldern, TW; Zinker, BA	1

Other Studies

2 other study(ies) available for cyclohexene and Diabetes Mellitus, Type 2

Article	Year
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi Journal of medicinal chemistry, 2006, Nov-02, Volume: 49, Issue:22 Topics: Animals; Biphenyl Compounds; Cyclohexenes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Models, Molecular; Rats; Rats, Zucker; Serine Proteinase Inhibitors; Structure-Activity Relationship; Triazoles; X-Ray Diffraction	2006
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit. Bioorganic & medicinal chemistry letters, 2007, Apr-01, Volume: 17, Issue:7 Topics: Animals; Blood Glucose; Chemistry, Pharmaceutical; Cyclohexenes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Enzyme Inhibitors; Female; Hypoglycemic Agents; Models, Chemical; Molecular Conformation; Phenethylamines; Pyrrolidines; Rats	2007

Article

Year

Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi

Journal of medicinal chemistry, 2006, Nov-02, Volume: 49, Issue:22

Topics: Animals; Biphenyl Compounds; Cyclohexenes; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Models, Molecular; Rats; Rats, Zucker; Serine Proteinase Inhibitors; Structure-Activity Relationship; Triazoles; X-Ray Diffraction

2006

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.

Bioorganic & medicinal chemistry letters, 2007, Apr-01, Volume: 17, Issue:7

Topics: Animals; Blood Glucose; Chemistry, Pharmaceutical; Cyclohexenes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Enzyme Inhibitors; Female; Hypoglycemic Agents; Models, Chemical; Molecular Conformation; Phenethylamines; Pyrrolidines; Rats

2007